Johnson & Johnson and its pharmaceutical subsidiary Janssen agreed on Tuesday with two counties in Ohio to compare $ 20.4 million to avoid a lengthy and costly federal trial on the opioid addiction epidemic.
Settlements with the Cuyahoga and Summit Counties are not taking on liability and are canceling Johnson & Johnson from the federal process, which is scheduled to commence this month in the northern district of Ohio.
the resource requirements and uncertainty of a process that continues to seek significant advances in overcoming the country's opioid crisis, "said Johnson & Johnson on Tuesday.
Johnson & Johnson will pay $ 5 million in addition to the reimbursement combined $ 1
A number of companies are expected to trial on October 21 in the Northern District of Ohio province to determine if manufacturers of prescription opioids have misrepresented the risks of long-term opioid use.
The Oklahoma judge ruled in a similar resolution in August Case against Johnson & Johnson and called on the company, 572 To pay millions of dollars to the state. In the judgment of Judge Thad Balkman, Johnson & Johnson and its affiliate were accused of urging physicians to prescribe opioids while the search risk was downplayed career. J & J has promoted a sales awareness program, funded articles in medical journals, and paid speakers.
None of these programs properly addressed search risks, and no commercial agent training was offered on the history of opioid use or addiction
"Defendant's opioid marketing in its myriad of forms was false, deceptive, and misleading," it says in the written decision.
Johnson & Johnson announced after the decision that this will be the case to file a complaint.
Purdue Pharma, the company that sold billions using OxyContin, a prescription painkiller, filed for bankruptcy in September after it reached a multi-billion dollar preliminary settlement. Purdue Pharma may also remove the filing from the federal process on October 21, as all parties wishing to claim damages from the company must be brought before a bankruptcy court.
The analgesic manufacturer still spends millions defending itself in litigation 2,600 governments and other bodies. Twenty-four states and the District of Columbia have not approved the proposal to settle the lawsuits.